S David Miller
Allergy & Immunology · North Dartmouth, MANPI 1063471126
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AstraZeneca at 42.4% of the total. Reporting peaked in 2019 at $3,861 and has fallen 95.6% since, to $168 in 2024.
Across 227 payments — averaging $56.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Mylan Inc.$2K
- Astrazeneca UK Limited$2K
- GSK$776
- Sanofi$241
- Takeda Pharmaceuticals U.S.A., Inc.$211
- plus $2K from 20 others
Across 489 payments — averaging $17,728 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$2.7M
- Amphastar Pharmaceuticals, Inc.$1.7M
- AstraZeneca$1.4M
- Teva Pharmaceuticals USA, Inc.$1.2M
- Cipla USA Inc.$496K
- Hikma Pharmaceuticals USA$404K
- plus $871K from 6 others
What the payments were for
- Consulting fees$9307%
- Speaking & faculty fees$2,65821%
- Travel & lodging$4,35934%
- Food & beverage$4,98539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 72 | $5,482 |
| Mylan Inc. | 2 | $2,490 |
| Astrazeneca UK Limited | 10 | $1,985 |
| GSK | 41 | $776 |
| Sanofi | 11 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $211 |
| Boehringer Ingelheim | 10 | $190 |
| Cipla USA Inc. | 1 | $168 |
| CSL Behring | 8 | $159 |
| Kaleo, Inc. | 7 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $125 |
| Biohaven Pharmaceuticals, Inc. | 2 | $122 |
| Shire North American Group Inc | 11 | $120 |
| Novartis | 7 | $116 |
| Pharming Healthcare, Inc. | 7 | $106 |
| Pfizer | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 5 | $91 |
| Regeneron Healthcare Solutions, Inc. | 3 | $76 |
| Covis Pharma GmbH | 4 | $70 |
| Biocryst US Sales Co., LLC | 2 | $57 |
| Genentech USA, Inc. | 2 | $34 |
| Seqirus USA Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $13 |
| Alk-abello, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wixela Inhub$2,490
- BREZTRI$2,363
- BEVESPI AEROSPHERE$1,520
- NURTEC ODT$220
How this compares
$12,932 in reported general payments places this provider in the 70th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in North Dartmouth
- Alan KatzNorth Dartmouth$20K
- Kathy DietlinNorth Dartmouth$14K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.